Name | Number of supported studies | Average coverage | |
---|---|---|---|
dendritic cell | 8 studies | 32% ± 10% | |
plasmacytoid dendritic cell | 6 studies | 19% ± 4% | |
CD8-positive, alpha-beta T cell | 4 studies | 36% ± 16% | |
regulatory T cell | 4 studies | 28% ± 20% | |
B cell | 3 studies | 21% ± 4% | |
plasma cell | 3 studies | 36% ± 20% | |
plasmablast | 3 studies | 18% ± 0% | |
macrophage | 3 studies | 18% ± 1% | |
CD4-positive, alpha-beta T cell | 3 studies | 39% ± 22% | |
myeloid cell | 3 studies | 24% ± 6% | |
monocyte-derived dendritic cell | 3 studies | 36% ± 12% |
Insufficient scRNA-seq data for expression of MIR155HG at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 210.91 | 575 / 578 | 84% | 3.55 | 966 / 1155 |
uterus | 92% | 45.94 | 156 / 170 | 83% | 3.60 | 382 / 459 |
kidney | 92% | 89.79 | 82 / 89 | 74% | 5.36 | 667 / 901 |
breast | 90% | 55.59 | 413 / 459 | 75% | 2.79 | 841 / 1118 |
ovary | 87% | 43.07 | 156 / 180 | 77% | 2.66 | 333 / 430 |
stomach | 83% | 58.81 | 299 / 359 | 76% | 3.24 | 217 / 286 |
intestine | 87% | 156.95 | 845 / 966 | 70% | 4.59 | 367 / 527 |
thymus | 86% | 73.11 | 560 / 653 | 60% | 2.68 | 361 / 605 |
esophagus | 68% | 33.02 | 980 / 1445 | 75% | 2.41 | 137 / 183 |
prostate | 95% | 91.67 | 233 / 245 | 44% | 1.13 | 221 / 502 |
bladder | 71% | 69.95 | 15 / 21 | 60% | 2.74 | 304 / 504 |
skin | 63% | 74.76 | 1144 / 1809 | 66% | 4.99 | 311 / 472 |
pancreas | 23% | 8.01 | 74 / 328 | 82% | 2.75 | 146 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 165.54 | 29 / 29 |
spleen | 100% | 535.68 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 93% | 83.20 | 1122 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 93% | 159.35 | 1241 / 1335 | 0% | 0 | 0 / 0 |
brain | 53% | 21.94 | 1390 / 2642 | 36% | 1.82 | 257 / 705 |
tonsil | 0% | 0 | 0 / 0 | 84% | 5.38 | 38 / 45 |
liver | 42% | 17.32 | 95 / 226 | 25% | 0.84 | 103 / 406 |
adrenal gland | 52% | 20.55 | 135 / 258 | 11% | 0.24 | 25 / 230 |
heart | 60% | 38.50 | 519 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 54% | 4924.45 | 505 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 18% | 0.76 | 14 / 80 |
muscle | 12% | 3.88 | 97 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002605 | Biological process | negative regulation of dendritic cell antigen processing and presentation |
GO_0002376 | Biological process | immune system process |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0030544 | Molecular function | Hsp70 protein binding |
Gene name | MIR155HG |
Protein name | HSPA8-interacting micropeptide miPEP155 (P155) |
Synonyms | |
Description | FUNCTION: Negatively regulates MHC class II antigen presentation in dendritic cells by interacting with the molecular chaperone HSPA8 and impairing its role in lysosomal antigen transport . Does not regulate the levels or activity of the MIR155HG microRNA from which miPEP155 is derived . . |
Accessions | C0HMA1 |